NEW YORK, Feb 1 – Genome Therapeutics has agreed to sequence the genome of an undisclosed pathogenic organism for Wyeth-Lederle Vaccines, the companies said Thursday.

The name of the pathogen remains confidential under the agreement, and Wyeth-Lederle Research spokesman Doug Petkus would say only that the genome “will be useful for our discovery efforts.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.